Reactogenicity and Immunogenicity of a Lyme Disease Vaccine in Children 2–5 Years Old
- 1 December 2000
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 31 (6), 1504-1507
- https://doi.org/10.1086/317479
Abstract
Two doses of a recombinant Lyme disease vaccine (15 and 30 microg) were administered to children 2-5 years old (0-1-month schedule) and were well tolerated. Both doses were highly immunogenic with geometric mean titers 1 month after vaccination of 4366 and 9877 ELISA units (EU)/mL, respectively. Nearly all subjects had antibody levels of > or = 1400 EU/mL, suggesting protective tick titre for one tick season.Keywords
This publication has 5 references indexed in Scilit:
- Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in childrenThe Journal of Pediatrics, 1999
- Alternative Vaccination Schedules (0, 1, and 6 Months Versus 0, 1, and 12 Months) for a Recombinant OspA Lyme Disease VaccineClinical Infectious Diseases, 1999
- Vaccination against Lyme Disease with RecombinantBorrelia burgdorferiOuter-Surface Lipoprotein A with AdjuvantNew England Journal of Medicine, 1998
- Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adultsVaccine, 1996
- Prospective Assessment of Lyme Disease in a School-Aged Population in ConnecticutThe Journal of Infectious Diseases, 1995